Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed Patients

Fungal infections have become a common threat in Intensive Care Units (ICU). The epidemiology of invasive fungal diseases (IFD) has been extensively studied in patients severely immunosuppressed over the last 20-30 years, however, the type of patients that have been admitted to hospitals in the last...

Descripción completa

Detalles Bibliográficos
Autores: Zaragoza R, Sole-Violan J, Cusack R, Rodriguez A, Reyes LF, Martin-Loeches I
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p14830
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/14830
Access Level:acceso abierto
Palabra clave:IPA
CAPA
IAPA
Aspergillus
sepsis
id ES_02bdfb4bc58c0ed949b268bf098fcd20
oai_identifier_str oai:fisabio.fundanetsuite.com:p14830
network_acronym_str ES
network_name_str España
repository_id_str
spelling Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed PatientsZaragoza RSole-Violan JCusack RRodriguez AReyes LFMartin-Loeches IIPACAPAIAPAAspergillussepsisFungal infections have become a common threat in Intensive Care Units (ICU). The epidemiology of invasive fungal diseases (IFD) has been extensively studied in patients severely immunosuppressed over the last 20-30 years, however, the type of patients that have been admitted to hospitals in the last decade has made the healthcare system and ICU a different setting with more vulnerable hosts. Patients admitted to an ICU tend to have older age and higher severity of disease. Moreover, the number of patients being treated in ICU are often immunosuppressed as a result of the widespread use of immunomodulatory agents, such as corticosteroids, chemotherapy, and biological agents. The development of Invasive Pulmonary aspergillosis (IPA) reflects a different clinical trajectory to affected patients. The increasing use of corticosteroids would probably explain the higher incidence of IPA especially in critically ill patients. In refractory septic shock, severe community-acquired pneumonia (SCAP), and acute respiratory distress syndrome (ARDS), the use of corticosteroids has re-emerged in order to decrease unacceptably high mortality rates associated with these clinical conditions. It is also pertinent to note that different reports have used different diagnosis criteria, and this might explain the different incidence rates. Another layer of complexity to better understand current IPA data is related to more aggressive acquisition of samples through invasive respiratory examinations.MDPI2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/14830DiagnosticsISSN: 20754418reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p148302026-06-11T12:45:17Z
dc.title.none.fl_str_mv Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed Patients
title Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed Patients
spellingShingle Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed Patients
Zaragoza R
IPA
CAPA
IAPA
Aspergillus
sepsis
title_short Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed Patients
title_full Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed Patients
title_fullStr Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed Patients
title_full_unstemmed Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed Patients
title_sort Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed Patients
dc.creator.none.fl_str_mv Zaragoza R
Sole-Violan J
Cusack R
Rodriguez A
Reyes LF
Martin-Loeches I
author Zaragoza R
author_facet Zaragoza R
Sole-Violan J
Cusack R
Rodriguez A
Reyes LF
Martin-Loeches I
author_role author
author2 Sole-Violan J
Cusack R
Rodriguez A
Reyes LF
Martin-Loeches I
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv IPA
CAPA
IAPA
Aspergillus
sepsis
topic IPA
CAPA
IAPA
Aspergillus
sepsis
description Fungal infections have become a common threat in Intensive Care Units (ICU). The epidemiology of invasive fungal diseases (IFD) has been extensively studied in patients severely immunosuppressed over the last 20-30 years, however, the type of patients that have been admitted to hospitals in the last decade has made the healthcare system and ICU a different setting with more vulnerable hosts. Patients admitted to an ICU tend to have older age and higher severity of disease. Moreover, the number of patients being treated in ICU are often immunosuppressed as a result of the widespread use of immunomodulatory agents, such as corticosteroids, chemotherapy, and biological agents. The development of Invasive Pulmonary aspergillosis (IPA) reflects a different clinical trajectory to affected patients. The increasing use of corticosteroids would probably explain the higher incidence of IPA especially in critically ill patients. In refractory septic shock, severe community-acquired pneumonia (SCAP), and acute respiratory distress syndrome (ARDS), the use of corticosteroids has re-emerged in order to decrease unacceptably high mortality rates associated with these clinical conditions. It is also pertinent to note that different reports have used different diagnosis criteria, and this might explain the different incidence rates. Another layer of complexity to better understand current IPA data is related to more aggressive acquisition of samples through invasive respiratory examinations.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/14830
url https://fisabio.portalinvestigacion.com/publicaciones/14830
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Diagnostics
ISSN: 20754418
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402675299221504
score 15,812455

Similares en LA Referencia